Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zenas BioPharma, Inc. - Common Stock (NQ:ZBIO)

30.19 -1.61 (-5.06%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 965,983
Open 32.00
Bid (Size) 30.00 (1)
Ask (Size) 30.39 (2)
Prev. Close 31.80
Today's Range 28.98 - 32.00
52wk Range 5.830 - 34.33
Shares Outstanding 41,793,412
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data
Via MarketBeat
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga

Performance

YTD
+235.1%
+235.1%
1 Month
+46.8%
+46.8%
3 Month
+83.5%
+83.5%
6 Month
+203.4%
+203.4%
1 Year
+42.5%
+42.5%

More News

Read More
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Zenas BioPharma Announces Positive Results from Phase 2 MoonStone Trial of Obexelimab in Relapsing Multiple Sclerosis
From Zenas BioPharma
Via GlobeNewswire
Chairman and CEO of Zenas BioPharma (ZBIO) Buys 36,928 Shares for $769,948
Via The Motley Fool
Topics Regulatory Compliance
Zenas Biopharma Raises $120 Million To Secure Global Rights To Multiple Sclerosis Drug
Via Benzinga
Zenas BioPharma and InnoCare Pharma Announce License Agreement Granting Zenas Rights for Three Autoimmune Product Candidates, Including Orelabrutinib, a BTK Inhibitor in Phase 3 Development for Multiple Sclerosis
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Zenas BioPharma
Via GlobeNewswire
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Zenas BioPharma
Via GlobeNewswire
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi, LLP
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
ZBIO DEADLINE: ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm – ZBIO
From The Rosen Law Firm PA
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and Avis Budget and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ibotta, NET Power, Zenas BioPharma, and BigBear and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharma
From Faruqi & Faruqi LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIO
From Pomerantz LLP
Via GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
From The Rosen Law Firm PA
Via GlobeNewswire
ROSEN, THE FIRST FILING FIRM, Encourages Zenas BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ZBIO
From The Rosen Law Firm PA
Via GlobeNewswire
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
From Zenas BioPharma
Via GlobeNewswire

Frequently Asked Questions

Is Zenas BioPharma, Inc. - Common Stock publicly traded?
Yes, Zenas BioPharma, Inc. - Common Stock is publicly traded.
What exchange does Zenas BioPharma, Inc. - Common Stock trade on?
Zenas BioPharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Zenas BioPharma, Inc. - Common Stock?
The ticker symbol for Zenas BioPharma, Inc. - Common Stock is ZBIO on the Nasdaq Stock Market
What is the current price of Zenas BioPharma, Inc. - Common Stock?
The current price of Zenas BioPharma, Inc. - Common Stock is 30.19
When was Zenas BioPharma, Inc. - Common Stock last traded?
The last trade of Zenas BioPharma, Inc. - Common Stock was at 10/28/25 04:00 PM ET
What is the market capitalization of Zenas BioPharma, Inc. - Common Stock?
The market capitalization of Zenas BioPharma, Inc. - Common Stock is 1.26B
How many shares of Zenas BioPharma, Inc. - Common Stock are outstanding?
Zenas BioPharma, Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.